ADH-503 free base [(Z)-Leukadherin-1] is a novel, potent, selective, orally bioactive and allosteric agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.

Complement factor D-IN-2 (extracted from WO2015130838A1, compound 190) is an inhibitor of complement factor D with the potential to be used for treating autoimmune diseases.

SB290157 TFA, the trifluoroacetate salt of SB-290157, is a novel, potent and selective antagonist of complement anaphylatoxin C3a receptor (IC50 = 200 nM) with the potential to be used in arthritis, diet-induced obesity, and metabolic dysfunction.

CP447697 is a lipophilic C5a receptor antagonist which can be used for the research of inflammation.

ADH-503 [(Z)-Leukadherin-1 choline] is a novel, potent, selective, orally bioactive and allosteric agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.

Danicopan (ACH4471) is a novel, selective and orally bioavailable small-molecule factor D inhibitor, which inhibits alternative pathway of complement (APC) activity.

Compstatin is a novel and potent 13-residue cyclic peptide acting as a potent inhibitor of the complement system C3 with species specificity.

Iptacopan (LNP-023; LNP023) HCl, the hydrochloride salt of Iptacopan, is an oral, potent and selective factor B inhibitor ( IC50 = 10 nM).

EG-00229 TFA, the trifluoroacetic acid form of EG00229, is a novel and potent Neuropilin 1 (NRP1) receptor antagonist with antitumor effects.